Applying to Clinical Trial: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Contact this trialFirst, we need to learn more about you.

PD-1 Inhibitor

REGN2810 for Brain Tumor

Recruiting2 awardsPhase 1 & 2

Minneapolis, Minnesota

This trial will take place in two phases. In phase 1, the safety and ideal dosage of the drug will be determined for children with recurrent or difficult-to-treat solid tumors or central nervous system tumors. In phase 2, the drug will be administered to children with newly diagnosed tumors of the brainstem or high-grade tumors elsewhere in the brain, either alone or in combination with radiation therapy, to see if it improves overall survival.

Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.

We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our and .

Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.

By clicking start, you agree to our